PRPONasdaqLaboratory Analytical InstrumentsUS GAAP · USD

Precipio, Inc.

Precipio, Inc. is a U.S.-based healthcare biotechnology company focused on cancer diagnostics. It develops and commercializes diagnostic products and pathology services through its clinical laboratory operations and product division.

Kysy yhtiöstä
Liikevaihto24,2milj. USD
+30,5 %v/v
Liikevoitto (EBIT)−1,2milj. USD
+71,5 %v/v
EBIT-marginaali−5,0%
+17,7 %-yks.v/v
Nettotulos−0,4milj. USD
+91,5 %v/v
Vapaa kassavirta0,4milj. USD
+66,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−20−100102030milj. USD2020: 7,4 milj. USD2020: EBIT −9,1 milj. USD20202021: 8,8 milj. USD2021: EBIT −9,6 milj. USD20212022: 9,8 milj. USD2022: EBIT −13 milj. USD20222023: 15 milj. USD2023: EBIT −7,6 milj. USD20232024: 19 milj. USD2024: EBIT −4,2 milj. USD20242025: 24 milj. USD2025: EBIT −1,2 milj. USD202524−1,2
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Precipio, Inc.

Liiketoiminta

Osuus liikevaihdosta
Pathology services89 %

Clinical laboratory testing and diagnostic pathology services performed through the New Haven CLIA lab.

Diagnostic products11 %

Cancer-focused laboratory products sold directly and through distributors.

Tuotteet

Raportoitu · osuus liikevaihdosta
88,7%11,3%FY2025100 %
  • Service Revenue Net88,7 %
  • Products11,3 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Precipio sells to laboratories, pathology practices, and healthcare organizations that need cancer diagnostic testing or related products. Its product business also reaches labs through national distributors, while its clinical lab services are used by patients and referring providers seeking pathology analysis.

Clinical laboratories

Buy diagnostic products and consumables for use in laboratory workflows and testing

Pathology practices and providers

Use pathology services for cancer-related diagnostic interpretation and testing

Healthcare distributors

Purchase and distribute products to reach laboratory customers nationwide

Patients and referring physicians

Receive pathology services through the company’s clinical laboratory operations

Strategia

Precipio’s strategy is built around using its own clinical laboratory as a development and validation engine for new diagnostic products. It also relies on distributor partnerships to broaden access to laboratories and accelerate commercialization of its cancer diagnostics portfolio.

Use the clinical lab as a product development platformLyhyt aikaväli

Internal testing and validation reduce development time and improve product fit for real workflows

Expand distributor-led product commercializationKeskipitkä aikaväli

National distributors extend reach into laboratory customers without building a large direct sales footprint

Build cancer diagnostics offerings that address misdiagnosisPitkä aikaväli

The company’s product pipeline is centered on solving diagnostic accuracy problems in oncology

Maantiede

Precipio is based in the United States and operates primarily through its New Haven, Connecticut clinical laboratory. The company states that it mainly serves the U.S. market, while its products may also be sold in other countries through global healthcare distributors.

Riskit

Precipio faces execution risk from dependence on reimbursement, billing operations, and access to capital, which are important for a company combining services and product development. It is also exposed to regulatory, trade, and tariff changes, as well as clinical and product-development risks typical of diagnostics businesses.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Liquidity and financing dependence1Trade and tariff exposure4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Liquidity and financing dependenceVaikutus: KriittinenTodennäköisyys: Matala

    The business needs external funding and revenue growth to support operations and obligations

    Kohdistuu: Company-wide

  2. Billing and reimbursement disruptionVaikutus: Korkea

    Pathology services depend on third-party billing systems and payer remittances, so interruptions can delay cash collection

    Kohdistuu: Pathology services

  3. Regulatory and reimbursement riskVaikutus: Korkea

    Clinical laboratory and diagnostic businesses are sensitive to healthcare regulation and payer policy

    Kohdistuu: U.S. diagnostics and pathology

  4. Trade and tariff exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Imported goods or supplier inputs may become more expensive under tariff changes

    Kohdistuu: Laboratory products supply chain

  5. Product development and validation riskVaikutus: Keskitaso

    New diagnostics require specimens, skilled staff, and successful validation before commercialization

    Kohdistuu: Pipeline products

Kysy Clarifolta: Precipio, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition and reimbursement adjustments

Pathology service revenue includes estimates for expected reimbursement and over-collections, which can change reported sales

Vaikutus: Affects quarterly service revenue and receivables

Allowance for credit losses

Billing collections depend on payer and patient remittances, so credit estimates affect net service revenue

Vaikutus: Affects reported net sales

Going concern and liquidity assumptions

Management must assess whether the company can continue operations and meet obligations

Vaikutus: Affects financial statement presentation and risk disclosure

Billing-related liabilities and recoveries

Disruptions in claims processing can create temporary funding, repayment, and write-off items

Vaikutus: Affects other liabilities and cash flow

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Precigen, Inc

PGEN · Pharmaceutical Preparations

Inovio Pharmaceuticals, Inc

INO · Pharmaceutical Preparations

Prelude Therapeutics Inc

PRLD · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

Veracyte, Inc

VCYT · Services-Medical Laboratories

Päivitetty: 24.9.2026

Precipio, Inc. (PRPO) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo